Cellectis (NASDAQ:CLLS) Rating Lowered to Sell at StockNews.com

Cellectis (NASDAQ:CLLS) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday.

Cellectis Stock Performance

NASDAQ CLLS opened at $2.69 on Thursday. Cellectis has a 12-month low of $0.96 and a 12-month high of $3.77. The company has a current ratio of 2.20, a quick ratio of 2.20 and a debt-to-equity ratio of 0.57. The company has a market cap of $149.51 million, a P/E ratio of -1.61 and a beta of 3.12. The company has a fifty day simple moving average of $2.70 and a 200 day simple moving average of $2.57.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Two Sigma Investments LP bought a new position in shares of Cellectis in the third quarter worth approximately $30,000. BNP Paribas Financial Markets lifted its stake in Cellectis by 44.4% in the fourth quarter. BNP Paribas Financial Markets now owns 15,800 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 4,856 shares during the period. Virtu Financial LLC purchased a new stake in Cellectis in the second quarter worth $46,000. Balyasny Asset Management LLC purchased a new stake in Cellectis in the third quarter worth $42,000. Finally, Envestnet Asset Management Inc. lifted its stake in Cellectis by 19.2% in the first quarter. Envestnet Asset Management Inc. now owns 20,501 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 3,305 shares during the period. 63.90% of the stock is currently owned by institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.